KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

AbCellera Biologics (ABCL) Research & Development (2020 - 2026)

AbCellera Biologics filings provide 7 years of Research & Development readings, the most recent being $46.7 million for Q1 2026.

  • Quarterly Research & Development rose 9.8% to $46.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $191.0 million through Mar 2026, up 12.04% year-over-year, with the annual reading at $186.8 million for FY2025, 11.7% up from the prior year.
  • Research & Development hit $46.7 million in Q1 2026 for AbCellera Biologics, down from $50.1 million in the prior quarter.
  • Across five years, Research & Development topped out at $55.0 million in Q3 2025 and bottomed at $26.4 million in Q1 2022.
  • Average Research & Development over 5 years is $40.3 million, with a median of $40.9 million recorded in 2024.
  • The largest annual shift saw Research & Development surged 113.46% in 2022 before it dropped 25.38% in 2024.
  • AbCellera Biologics' Research & Development stood at $28.2 million in 2022, then soared by 72.14% to $48.6 million in 2023, then decreased by 5.24% to $46.1 million in 2024, then increased by 8.72% to $50.1 million in 2025, then dropped by 6.85% to $46.7 million in 2026.
  • Per Business Quant, the three most recent readings for ABCL's Research & Development are $46.7 million (Q1 2026), $50.1 million (Q4 2025), and $55.0 million (Q3 2025).